Author: Lindsay Clarke
Date: December 15th, 2011
In a time where health care spending is sky-rocketing, where will the public draw the line? Evidence from comparative effectiveness research (CER) is increasingly being used in health-care treatment decision-making around the globe, yet there is still a lot to be learned about how the public feels and where they think the lines should be drawn.
Despite increasing concerns about health care costs, a new public opinion survey from the Harvard School of Public Health and the Alliance for Aging Research, found little support among Americans for decisions that limit the use of high-cost prescription drugs. The majority opposes decisions made by government or private health insurance plans where a drug or treatment isn’t paid for because the benefits aren’t believed to justify the costs. The survey results really emphasize the need for a careful balancing of measures to control health care costs and measures to ensure that Americans receive high quality health care at all stages of life. These results are particularly timely with PCORI still in its infancy and many policies surrounding CER in the U.S. still to be made. To learn more about the survey and to hear from the experts involved, listen-in to the Webcast Briefing: Moving Along the Guiderails at 11:00 AM on December 22nd.